

[Telmisartan + amlodipine](#)

Essential medicine status

Section:

[12. Cardiovascular medicines 12.3. Antihypertensive medicines](#)

ATC codes: [C09DB04](#)

Indication

Essential hypertension ICD11 code: [BA00.Z](#)

INN

Telmisartan + amlodipine

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid: 40 mg + 5 mg ; 80 mg + 5 mg ; 80 mg + 10 mg

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and C08CA Dihydropyridine derivatives (for amlodipine)

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Wikipedia

[Telmisartan + amlodipine](#)

DrugBank

[Telmisartan](#),

[Amlodipine](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroups, C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and C08CA Dihydropyridine derivatives (for amlodipine), be specified as therapeutic alternatives under the square box listing for telmisartan + amlodipine on the EML.